MARKET

REXN

REXN

REXAHN PHARMA
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.839
+0.019
+1.03%
Closed 16:00 03/27 EDT
OPEN
1.910
PREV CLOSE
1.820
HIGH
1.910
LOW
1.670
VOLUME
13.78K
TURNOVER
--
52 WEEK HIGH
9.18
52 WEEK LOW
1.263
MARKET CAP
7.39M
P/E (TTM)
-0.8414
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of REXN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REXN stock price target is 3.000 with a high estimate of 3.000 and a low estimate of 3.000.

EPS

REXN News

More
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Rexahn Pharma Shares See Spike In Volume; Hearing Co. Granted US Patent '101 For 'Quinoxalinyl-piperazinamide methods of use'
  • Benzinga · 02/25 15:10
  • CYBR, BBBY among premarket losers
  • Seeking Alpha - Article · 02/12 14:17
  • Mid-Afternoon Market Update: Dow Rises 50 Points; Sprint Shares Spike Higher
  • Benzinga · 02/11 19:34

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About REXN

Rexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.
More

Webull offers kinds of Rexahn Pharmaceuticals, Inc. stock information, including NASDAQ:REXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REXN stock news, and many more online research tools to help you make informed decisions.